Eli Lilly and Company (LLY) |
735.275 10.405 (1.44%) 04-26 12:15 |
Open: | 723.48 |
High: | 737.45 |
Low: | 721.5 |
Volume: | 838,689 |
Market Cap: | 699,074(M) |
PE Ratio: | 126.77 |
Exchange: | New York Stock Exchange |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 793.67 |
Resistance 1: | 764.88 |
Pivot price: | 746.65 |
Support 1: | 718.30 |
Support 2: | 597.63 |
52w High: | 800.78 |
52w Low: | 392.26 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
EPS | 5.810 |
Book Value | 11.980 |
PEG Ratio | 1.18 |
Gross Profit | 0.000 |
Profit Margin (%) | 15.36 |
Operating Margin (%) | 34.14 |
Return on Assets (ttm) | 11.9 |
Return on Equity (ttm) | 48.4 |
Thu, 25 Apr 2024
Eli Lilly & Co. stock outperforms competitors despite losses on the day - MarketWatch
Wed, 24 Apr 2024
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Wed, 24 Apr 2024
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
Wed, 24 Apr 2024
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings? - Zacks Investment Research
Tue, 23 Apr 2024
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Tue, 23 Apr 2024
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |